Close Menu

Beckman Coulter

The company, which is being purchased by Danaher, did not report its earnings for the fourth quarter, but based on what it had previously reported for the first three quarters, revenues for the final quarter of 2010 were $986.5 million.

At the Association for Mass Spectrometry's Applications to the Clinical Lab meeting this week, proteomics researchers highlighted the need for higher-throughput assays, with several introducing automated SISCAPA workflows employing instruments from vendors including Agilent Technologies and Thermo Fisher Scientific.

The action is an amendment to a lawsuit in which plaintiffs argued that the company, its board, and certain of its officers breached their fiduciary duty in connection to the company's trouble with its Accutn1 troponin test last year.

Beckman Coulter said that it's board of directors will pay a quarterly dividend of $.19 per share.

Today's announcement ends two months of speculation about the future of Beckman Coulter as Danaher continues to add to its life sciences tools portfolio.

Wayne Cowens joined NanoString from Genomic Health this week, while Roche proposed new members for its board of directors, and BioNanomatrix hired Erik Holmlin as its new CEO; and more.

The announcement follows developments last year in which next-gen sequencing uncovered fragments of a porcine circovirus within a rotavirus vaccine, prompting the US Food and Drug Administration to consider the use of sequencing as a quality-control measure for vaccines and biologics.

Its time estimate is based on the current status of its clinical trial for the test, including site and patient enrolment, and preliminary myocardial infarction incidence rates observed.

The test under development will be used in an upcoming clinical trial to determine which patients may be suitable for treatment with an immunotherapy candidate for non-small cell lung cancer.

Transgene plans to use the tests from Ventana and Beckman Coulter to analyze which subpopulations of patients with advanced NSCLC will likely respond best to the MVA-MUC1-IL2 immunotherapeutic in combination with first-line therapy.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.